Creating site and patient centric solutions for a challenging antibiotic pharmacokinetic (PK) study

Beyond the Headlines: What ASCO 2025 Taught Us About the Future of Cancer Care

FDA's plan to Phase Out Animal testing: Implications for Drug Development

In April 2025, the U.S. Food and Drug Administration (FDA) announced its intention to phase out animal testing requirements for monoclonal antibodies and other pharmaceuticals . While this milestone signals progress toward more ethical and innovative drug development approaches, its implications warrant careful examination.

Increasing trial productivity: Addressing site-specific challenges to improve site engagement

Improving clinical trials: Unlock the power of productivity through protocol design

Fortrea’s Dr. Barbara Gillespie co-authors pivotal paper rethinking membranous nephropathy trials in the anti-PLA2R era

ARVO 2025: Advancing ophthalmology research through innovation and collaboration